Shares of Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) shot up 6.1% during trading on Monday . The company traded as high as $4.56 and last traded at $4.55, with a volume of 763,169 shares traded. The stock had previously closed at $4.29.

A number of brokerages recently commented on KERX. Morgan Stanley reiterated a “hold” rating on shares of Keryx Biopharmaceuticals in a research report on Saturday, April 30th. Zacks Investment Research lowered Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 3rd. Brean Capital lowered Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 2nd. FBR & Co lowered Keryx Biopharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $16.00 to $7.00 in a research report on Tuesday, August 2nd. Finally, Cowen and Company restated a “hold” rating on shares of Keryx Biopharmaceuticals in a research report on Saturday, April 30th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $7.75.

The stock’s market cap is $473.35 million. The company’s 50 day moving average is $6.25 and its 200-day moving average is $5.23.

Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its earnings results on Monday, August 1st. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.14. The business earned $9.30 million during the quarter, compared to analysts’ expectations of $8.60 million. The company’s revenue was up 272.0% on a year-over-year basis. During the same period in the previous year, the company earned ($0.26) EPS. On average, equities analysts expect that Keryx Biopharmaceuticals Inc. will post ($1.23) earnings per share for the current fiscal year.

In other Keryx Biopharmaceuticals news, CFO Scott A. Holmes sold 4,935 shares of the stock in a transaction dated Friday, July 29th. The stock was sold at an average price of $7.36, for a total value of $36,321.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

An institutional investor recently bought a new position in Keryx Biopharmaceuticals stock. Royce & Associates LLC acquired a new position in Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 341,725 shares of the biopharmaceutical company’s stock, valued at approximately $1,726,000. Royce & Associates LLC owned 0.32% of Keryx Biopharmaceuticals as of its most recent filing with the SEC.

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.